Darunavir and Apixaban (Eliquis 5 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A and P-glycoprotein inhibition increases apixaban exposure.
Clinical significance and safety
For ritonavir-boosted darunavir (PREZISTA/ritonavir), apixaban requires dose- and indication-specific management, and some circumstances require avoiding the combination. The prescriber should check the apixaban label and bleeding risk rather than applying an automatic adjustment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.